Journal
Frontiers in Medicine
Publication Date
1-1-2025
Volume
12
First Page
1548590
Document Type
Open Access Publication
DOI
10.3389/fmed.2025.1548590
Rights and Permissions
Masarova L, Reeves BN, El Chaer F, Foltz L, Tashi T, Abu-Zeinah G, Lucas J, Halpern AB, Maze D, Qin A, Safah H, Lan F, O'Connell CL, Goel S, Rein L, Fang B, How J, Babu S, Li Z, Cerquozzi S, Oh ST, Hunter AM, Podoltsev N, Vachhani P, Yacoub A, Cunningham JM, Hillis C, Otoukesh S, Zagrijtschuk O, Castro H and Bose P (2025) A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial. Front. Med. 12:1548590. doi: 10.3389/fmed.2025.1548590 © 2025 Masarova, Reeves, El Chaer, Foltz, Tashi, Abu-Zeinah, Lucas, Halpern, Maze, Qin, Safah, Lan, O’Connell, Goel, Rein, Fang, How, Babu, Li, Cerquozzi, Oh, Hunter, Podoltsev, Vachhani, Yacoub, Cunningham, Hillis, Otoukesh, Zagrijtschuk, Castro and Bose. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Recommended Citation
Masarova, Lucia; Oh, Stephen T; and et al., "A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial." Frontiers in Medicine. 12, 1548590 (2025).
https://digitalcommons.wustl.edu/oa_4/7536
Department
ICTS (Institute of Clinical and Translational Sciences)
